CordenPharma Adds Highly Potent API Laboratory to its Colorado Facility

Article

The lab, which is currently available to customers, can handle highly potent compounds.

CordenPharma announced on Oct. 19, 2020 that it has completed the construction of its highly potent API laboratory in its Boulder, CO facility.

The lab, which is currently available to customers, can handle highly potent compounds with an OEL as low as 1 ng/m3, according to a company press release.

“Our new laboratory in Colorado is part of a development capacity expansion to address the strong market demand. This additional capacity benefits customers by expediting the onboarding of new projects,” said Jason Bertola, director of CordenPharma’s Global Highly Potent & Oncology Platform, in the press release.

Source: CordenPharma​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Recent Videos
Behind the Headlines episode 6
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content
Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Abzena Expands Analytical Services with GMP Cell-Based Potency Testing in US and UK

Feliza Mirasol
November 22nd 2024
Article

The company has expanded its early and late phase analytical capabilities by including GMP cell-based potency assays at its sites in Cambridge, UK, and San Diego, Calif.

Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain

Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain

Jill Murphy
November 14th 2023
Podcast

In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Circio and Certest to Collaborate on LNP Formulations

Feliza Mirasol
November 21st 2024
Article

The companies will collaborate to create and test circVec DNA–LNP formulations for use in potential therapeutic applications.

Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution

Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution

Jill Murphy
June 20th 2023
Podcast

Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

CDMO SEKISUI Expands its CGMP Biopharma Manufacturing Capacity

Feliza Mirasol
November 20th 2024
Article

SEKISUI has used a £15.7 million (US$20.7 million) investment to expand its clinical-grade drug substance manufacturing at its UK site.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Alentis Therapeutics to Advance Anti-Claudin-1 ADCs to Treat Solid Tumors on $181.4 Million Financing

Feliza Mirasol
November 19th 2024
Article

Financing from OrbiMed, Novo Holdings, Jeito Capital, and others will enable Alentis Therapeutics to advance its pipeline of Claudin-1-targeted ADCs for treating solid tumors.